Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL

Abstract: De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable responses. To identify such combinations, we previously pe...

पूर्ण विवरण

ग्रंथसूची विवरण

मुख्य लेखकों:	Kallesh D. Jayappa, Craig A. Portell, Vicki L. Gordon, Brian J. Capaldo, Stefan Bekiranov, Mark J. Axelrod, L. Kyle Brett, Julia D. Wulfkuhle, Rosa I. Gallagher, Emanuel F. Petricoin, Timothy P. Bender, Michael E. Williams, Michael J. Weber
स्वरूप:	Artigo
भाषा:	Inglês
प्रकाशित:	Elsevier 2017-06-01
श्रृंखला:	Blood Advances
ऑनलाइन पहुंच:	http://www.sciencedirect.com/science/article/pii/S2473952920302056
टैग:	टैग जोड़ें कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!